Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Withdrawal symptoms commonly occur during tapering and/or after discontinuation of antidepressant drugs, particularly selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Withdrawal symptomatology does not necessarily subside within a few weeks and may be associated with other manifestations of behavioral toxicity (loss of treatment efficacy, refractoriness, switch into mania/hypomania, or paradoxical reactions). The oppositional model of tolerance provides a pathophysiologic basis for understanding and managing withdrawal syndromes. Reintroducing the antidepressant that was initially used or switching from one antidepressant to another to suppress symptomatology, as suggested by current guidelines, may actually aggravate the state of behavioral toxicity and be detrimental in the long run. Alternative strategies that do not encompass continuation of antidepressant treatment are required, but there is currently lack of adequate research for guiding the clinical approach. Some tentative suggestions are provided.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A specific subgroup of the acute withdrawal syndrome is the rebound disorder, where previously known symptoms reoccur with greater intensity (Cosci and Chouinard, 2020; Fava and Cosci, 2019).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Fava and Cosci, 2019
In the citing paper
“The prolonged use of antidepressant medications, similar to other psychotropic substances, can lead to sustained neurophysiological adaptations (Ashton, 1991; Cosci and Chouinard, 2020; Fava and Cosci, 2019; Horowitz et al., 2023; Lerner and Klein, 2019).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Fava and Cosci, 2019
In the citing paper
“One recently identified main concern is the potential for acute and persistent post-acute (protracted) withdrawal symptoms when the medication is discontinued (Boland et al., 2024; Chouinard and Chouinard, 2015; Fava and Cosci, 2019; Hengartner et al., 2019; Lerner and Klein, 2019; Massabki and Abi-Jaoude, 2021).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Fava and Cosci, 2019
In the citing paper
“Rather, characteristics of the individual may be more important; posited, among other potentially predisposing factors, are lengthy drug treatment, medication switches, abrupt discontinuation, inadequate tapering, prior difficulty in withdrawal or other adverse drug events and physiological vulnerability.20,23,30,41–43”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [30]
In the citing paper
“The narratives analyzed in this study likewise indicate that consumers are able to distinguish drug withdrawal from the symptoms of the original illness, since withdrawal symptoms are experienced as more intense, urgent, and often unprecedented, that is, qualitatively different.28,30,35”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [30]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mechanisms of stress in the brain
McEwen, B. S., Bowles, N. P., Gray, J. D., Hill, M. N., Hunter, R. G., Karatsoreos, I. N., & Nasca, C. (2015) · Nature Neuroscience · doi:10.1038/nn.4086 · Cited by 1,386
Cuthbert, B. N. (2014) · World Psychiatry · doi:10.1002/wps.20087 · Cited by 1,377
X-ray structures and mechanism of the human serotonin transporter
Coleman, J. A., Green, E. M., & Gouaux, E. (2016) · Nature · doi:10.1038/nature17629 · Cited by 668
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Self-citationExploring comorbidity within mental disorders among a Danish national population
Plana-Ripoll, O., Pedersen, C. B., Holtz, Y., Benros, M. E., Dalsgaard, S., de Jonge, P., Fan, C. C., Degenhardt, L., Ganna, A., Greve, A. N., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3658 · Cited by 584
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
Self-citationFava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Self-citation
Cited by
Time for united action on depression: a Lancet–World Psychiatric Association Commission
Herrman, H., Patel, V., Kieling, C., Berk, M., Buchweitz, C., Cuijpers, P., Furukawa, T. A., Kessler, R. C., Kohrt, B. A., Maj, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02141-3 · Cited by 1,104
Effect of Electroacupuncture on Insomnia in Patients With Depression: A Randomized Clinical Trial
Yin, X., Li, W., Liang, T., Lu, B., Yue, H., Li, S., Zhong, V. W., Zhang, W., Li, X., Zhou, S., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.20563 · Cited by 159
Gastaldon, C., Schoretsanitis, G., Arzenton, E., Raschi, E., Papola, D., Ostuzzi, G., Moretti, U., Seifritz, E., Kane, J. M., Trifirò, G., et al. (2022) · Drug Safety · doi:10.1007/s40264-022-01246-4 · Cited by 64
Hengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
Metadata
- Authors
- Fava, G. A., & Cosci, F.
- Affiliations
- Erie County Medical Center (US)
- University of Florence (IT)
- Corresponding author
- Fava, Giovanni A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2019-11-26
- Volume
- 80
- Issue
- 6
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W2990135086
- Cited by
- 69
- References
- 40
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 8 · 2023: 15 · 2022: 11 · 2021: 10 · 2020: 9 · 2019: 1
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- antidepressant withdrawal syndrome, antidepressant discontinuation, antidepressant tapering, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressant switching, treatment refractoriness, behavioral toxicity
- MeSH terms
- Antidepressive Agents, Drug Administration Schedule, Drug Therapy, Combination, Humans, Metabolic Clearance Rate, Risk Factors, Substance Withdrawal Syndrome, Syndrome, Retreatment, Drug Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.